Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: J Allergy Clin Immunol. 2021 Dec 28;149(6):1981–1991. doi: 10.1016/j.jaci.2021.11.025

Table I.

Characteristics of participants in ICS response studies.

A. GSK cohort
Characteristics Phase IIB studies Phase IIIA studies HZA 106837
Total patients 1,125 679 868
Age (y) 42.1±16.8 44.2±15.6 42.7±14.7
Sex: %female 61.2 58.6 68.6
BMI (kg/m2) 27.9±6.7 27.9±5.2 27.6±5.9
Height (cm) 167.9±13.4 165.9±7.8 163.9±8.8
Asthma duration (y) 17.7±13.4 14.9±13.0 15.7±11.8
FEV1 at baseline (% predicted) 69.9±10.1 69.2±10.4 71.7±11.8
FEV1 change (% predicted) 7.2±13.4 6.9±13.0 6.1±11.8
B. GERA cohort
Characteristics Asthma patients with exacerbation Asthma patients without exacerbation
Total patients 3,097 2,613
Age (y) 63.8±14.0 63.4±15.2
Sex: %female 2168 (70.0%) 1765 (67.5%)
BMI (kg/m2) 29.2±6.2) 28.6±6.3
Smoking status: %ever smoker 1378 (45.9%) 1027 (40.9%)
Allergic rhinitis status 1404 (45.3%) 1113 (42.6%)
Gastroesophageal reflux disease 983 (31.7%) 651 (24.9%)
C. GALA II study
Characteristics Asthma patients with exacerbation Asthma patients without exacerbation
Total patients 567 287
Age (y) 11.9±3.1 12.5±3.3
Sex: %female 246 (43.4%) 119 (41.5%)
D. SAGE study
Characteristics Asthma patients with exacerbation Asthma patients without exacerbation
Total patients 256 237
Age (y) 13.2±3.4 13.8±3.4
Sex: %female 123 (48.0%) 103 (43.5%)
E. SLOVENIA cohort
Characteristics ICS non-responders ICS responders
Total patients 94 72
Age (y) 10.7±3.2 11.2±3.5
Sex: %female 35 (37.2%) 33 (45.8%)
F. UK Biobank participants
Characteristics Asthma patients Healthy controls
Total patients 19,216 162,637
Age (y) 55.8±8.4 57.1±8.3
Sex: %female 62.2 55.4
BMI (kg/m2) 27.9±5.0 27.1±4.7
Smoking status: %ever smoker 57.4 58.1

Continuous values are shown as mean±standard error. GSK data is derived from Table I by Mosteller et al11.